Pipeline

EVOLVE-104 is a first-in-class biotherapeutic with potential to address a wide range of solid tumors with high selectivity. EVOLVE-105 represents a best- in-class molecule to improve patient outcomes in relapsed or treatment refractory B cell lymphoma.  Our best-in-class EVOLVE-106 program addresses important unmet needs in selected solid tumor targets. EVOLVE-101 is a first-in-class molecule targeting a novel tumor antigen for the treatment of B cell malignancies and particular myeloid malignancies.  We anticipate entering the clinic with our first program in 2024.